In Depth 11 Jun 2025 Can gene therapy treat vision loss? Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness. June 11, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2019 The Top 20 Women in Leading Biotech Roles in Europe The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […] May 21, 2019 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Sep 2018 How to Overcome Failure as a Biotech Company Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of ophthalmic gene therapy company Horama, shared her personal story of how she saved her previous company, Trophos, from an almost certain failure. The mission of […] September 25, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2018 Update: French Biotech Raises €22M for a Gene Therapy Trial in Retinitis Pigmentosa Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The funds will be mainly directed at developing Horama’s gene therapy for retinitis pigmentosa. Published on 08/10/2017 Horama has raised a second fundraising round that will support […] September 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […] July 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Dec 2017 The Biggest Biotech News of 2017: What Happened This Year? Still catching up on news? We’ve picked out the most exciting things that happened besides clinical results and finance. Here’s the biggest biotech news of 2017. We’ve been recapping the year with the most stellar biotechs, most heartening clinical successes and most disappointing failures in biotech. But what else happened this year? There’s more news […] December 27, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2017 French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops gene therapies to treat genetic diseases affecting vision. The company will now start a Phase I/II clinical trial that will recruit 12 patients at the Nantes […] October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email